benralizumab + benralizumab + Placebo

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Eosinophilic Chronic Rhinosinusitis

Conditions

Eosinophilic Chronic Rhinosinusitis

Trial Timeline

Jun 1, 2016 → Mar 27, 2017

NCT ID

NCT02772419

About benralizumab + benralizumab + Placebo

benralizumab + benralizumab + Placebo is a phase 2 stage product being developed by Kyowa Kirin for Eosinophilic Chronic Rhinosinusitis. The current trial status is completed. This product is registered under clinical trial identifier NCT02772419. Target conditions include Eosinophilic Chronic Rhinosinusitis.

What happened to similar drugs?

6 of 17 similar drugs in Eosinophilic Chronic Rhinosinusitis were approved

Approved (6) Terminated (2) Active (9)

✅BenralizumabAstraZenecaApproved

✅Benralizumab Prefilled SyringeAstraZenecaApproved

✅DupilumabSanofiApproved

✅Dupilumab + PlaceboSanofiApproved

✅Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]Regeneron PharmaceuticalsApproved

🔄Tezepelumab + TezepelumabAstraZenecaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02772419	Phase 2	Completed	Jun 1, 2016	Mar 27, 2017	Eosinophilic Chronic Rhinosinusitis

Competing Products

20 competing products in Eosinophilic Chronic Rhinosinusitis

See all competitors

Product	Company	Stage	Hype Score
KHK4563 + KHK4563 + KHK4563 + Placebo	Kyowa Kirin	Phase 2	35
SHR-1703 + SHR-1703 Placebo	Jiangsu Hengrui Medicine	Phase 2	35
NS-229 + Placebo	Nippon Shinyaku	Phase 2	42
Esomeprazole + Budesonide	AstraZeneca	Phase 2/3	38
Tezepelumab + Tezepelumab	AstraZeneca	Phase 3	44
Benralizumab	AstraZeneca	Approved	43
Cohort	AstraZeneca	Pre-clinical	26
Benralizumab + Matching placebo	AstraZeneca	Phase 3	32
Benralizumab	AstraZeneca	Phase 3	44
Benralizumab + Mepolizumab + Placebo to Mepolizumab + Placebo to Benralizumab	AstraZeneca	Phase 3	44
Benralizumab Prefilled Syringe	AstraZeneca	Approved	50
benralizumab	AstraZeneca	Pre-clinical	33
Benralizumab + Placebo	AstraZeneca	Phase 3	44
Benralizumab	AstraZeneca	Phase 3	47
Benralizumab + Placebo	AstraZeneca	Phase 3	32
Tezepelumab + Placebo	AstraZeneca	Phase 2	42
Benralizumab + Placebo	AstraZeneca	Phase 2/3	38
inhaled/swallowed budesonide + viscous/swallowed budesonide	AstraZeneca	Pre-clinical	26
Benralizumab + 129 Xenon	AstraZeneca	Pre-clinical	30
Benralizumab + Placebo	AstraZeneca	Phase 3	40